<DOC>
	<DOCNO>NCT00255723</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Radiation therapy use high-energy x-ray kill cancer cell . Giving combination chemotherapy radiation therapy autologous stem cell transplant , use peripheral stem cell bone marrow patient , may allow chemotherapy give cancer cell kill . Giving combination chemotherapy together radiation therapy autologous stem cell transplant may effective treatment Hodgkin 's lymphoma . PURPOSE : This phase II trial study well combination chemotherapy radiation therapy work treat patient undergo autologous stem cell transplant relapse refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether event-free survival patient low high-intermediate risk , relapse refractory Hodgkin 's lymphoma improve treated cytoreductive combination chemotherapy follow radiotherapy , high-dose combination chemotherapy , autologous stem cell transplantation . Secondary - Determine toxic effect regimen patient . OUTLINE : Patients stratify accord risk factor ( low low-intermediate risk [ 0-1 risk factor ] vs high-intermediate risk [ 2 risk factor ] ) . - ICE-based cytoreductive chemotherapy : Patients assign 1 2 treatment group . - Group I ( patient low low-intermediate risk disease ) : Patients receive ICE comprise ifosfamide IV carboplatin IV day 2 etoposide IV 1 hour daily day 1-3 . Patients receive ifosfamide IV twice day 15 , carboplatin IV day 17 etoposide IV 1 hour twice daily day 15-17 . - Group II ( patient high-intermediate risk disease ) : Patients receive ifosfamide IV twice day 1 17 , carboplatin IV day 3 19 , etoposide IV 1 hour twice daily day 1-3 17-19 . In group , patient undergo stem cell collection either first second OR first second course ICE . - Stem cell mobilization collection : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 5 continue stem cell collection complete . Patients undergo maximum 5 daily apheresis session . Patients mobilize few require minimal number stem cell repeat apheresis high-dose G-CSF alone undergo bone marrow harvest . Patients proceed radiotherapy , high-dose chemotherapy ( HDC ) , autologous stem cell transplant ( ASCT ) OR noncross-resistant chemotherapy base response ICE-based cytoreductive chemotherapy . - Restaging study : Patients undergo restaging study CT scan positron emission tomography ( PET ) . Patients chemosensitive normal PET scan proceed radiotherapy , HDC , ASCT . Patients progress ICE , respond abnormal PET scan , proceed noncross-resistant chemotherapy comprise gemcitabine hydrochloride , vinorelbine , doxorubicin HCl liposome ( GND ) . - GND chemotherapy : Patients receive gemcitabine hydrochloride IV , vinorelbine IV , doxorubicin HCl liposome IV day 1 , 15 , 29 , 43 . Patients proceed radiotherapy , HDC , ASCT absence disease progression . - Radiotherapy : Within 2 week completion ICE GND regimen , patient history prior radiotherapy receive radiotherapy accord stratification disease extent ( isolated lymph node vs ≥ 2 contiguous nodal-based mass without extensive small-volume lymphadenopathy v extensive small-volume lymphadenopathy ) . These patient undergo either involved-field radiotherapy ( IFRT ) twice daily 1-2 week , total lymphoid irradiation ( TLI ) twice daily 1 week , concurrently . - HDCT : Patients undergo TLI OR IFRT TLI receive high-dose cyclophosphamide IV twice daily etoposide IV daily day -5 -2 . Patients undergo IFRT OR undergo radiotherapy receive high-dose cyclophosphamide IV twice daily etoposide IV daily day -6 -3 carmustine IV day -2 . - ASCT : Patients undergo ASCT reinfusion bone marrow , harvest , day -1 0 . Patients receive G-CSF beginning day 5 continue blood count recover . After completion study treatment , patient follow periodically 15 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histologic diagnosis Classical Hodgkin 's Lymphoma . Lymphocyte predominant histology exclude . Primary refractory relapse disease proven biopsy fine needle aspiration ( cytology ) involve site Failure doxorubicin nitrogen mustard contain frontline therapy 18FfluorodeoxyglucosePET scan demonstrate PET avid disease Cardiac ejection fraction great 45 % , measure since last chemotherapy . Adjusted diffuse capacity great 50 % pulmonary function testing , measure since last chemotherapy Serum creatinine &lt; = 1.5 mg/dl ; creatinine &gt; 1.5 mg/dl measure 12 24hour creatinine clearance must &gt; 60 ml/minute . ANC &gt; 1000/μl Platelets &gt; 50,000/μl Total bilirubin &lt; = 2.0 mg/dl absence history Gilbert 's disease . Females childbearing age must acceptable form birth control . Age 18 72 HIV I II negative . Patients guardian must capable provide informed consent . Histology Lymphocyte predominant subtype Hodgkin 's Lymphoma Prior treatment carboplatin , cisplatin , ifosfamide , gemcitabine , vinorelbine Hepatitis B surface antigen positive . Known pregnancy breastfeed . Medical illness unrelated Hodgkin 's Lymphoma , , opinion attend physician and/or principal investigator , preclude administer chemotherapy safely . History malignancy diseasefree interval &lt; 5 year , exclude curatively treat cutaneous basal cell squamous cell carcinoma carcinoma insitu cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>